Ma­teon punts failed late-stage can­cer drug, ax­es staffers; Medi­vir boost­ed by os­teoarthri­tis da­ta

⇨ The pen­ny stock biotech Ma­teon Ther­a­peu­tics $MATN, for­mer­ly Ox­i­Gene, says it is scrap­ping a Phase II/III ovar­i­an can­cer study of CA4P in com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.